PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Monalizumab (Primary) ; Saruparib (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms PRISM
- 17 Jan 2025 New trial record